Brainsway price target raised to $30 from $24 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Brainsway (BWAY) to $30 from $24 and keeps a Buy rating on the shares. The company recently announced premarket approval receipt for Neurolief’s Proliv RX system, a class III device, as an adjunctive treatment for adult patients suffering from major depressive disorder who have failed to achieve satisfactory improvement from at least one previous antidepressant medication, for use at home or in the clinic, the analyst tells investors in a research note.